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SUMMARY
In clinical practice, an informative and practically useful treatment rule should be simple and 
transparent. However, because simple rules are likely to be far from optimal, effective methods to 
construct such rules must guarantee performance, in terms of yielding the best clinical outcome 
(highest reward) among the class of simple rules under consideration. Furthermore, it is important 
to evaluate the benefit of the derived rules on the whole sample and in pre-specified subgroups 
(e.g., vulnerable patients). To achieve both goals, we propose a robust machine learning method to 
estimate a linear treatment rule that is guaranteed to achieve optimal reward among the class of all 
linear rules. We then develop a diagnostic measure and inference procedure to evaluate the benefit 
of the obtained rule and compare it with the rules estimated by other methods. We provide 
theoretical justification for the proposed method and its inference procedure, and we demonstrate 
via simulations its superior performance when compared to existing methods. Lastly, we apply the 
method to the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial on major 
depressive disorder and show that the estimated optimal linear rule provides a large benefit for 
mildly depressed and severely depressed patients but manifests a lack-of-fit for moderately 
depressed patients.
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1. Introduction
Heterogeneity in patient response to treatment is a long-recognized challenge in the clinical 
community. For example, in adults affected by major depression, only around 30% of 
patients achieve remission with a single acute phase of treatment (Trivedi et al., 2006; Rush 
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et al., 2004); the remaining 70% of patients require augmentation of the current treatment or 
a switch to a new treatment. Thus, a universal strategy that treats all patients by the same 
treatment is inadequate, and individualized treatment strategies are required to improve 
response in individual patients. In this regard, rapid advances in technologies for collecting 
patient-level data have made it possible to tailor treatments to individual patients based on 
specific characteristics, thereby enabling the new paradigm of personalized medicine.
Statistical methods have been proposed to estimate optimal individualized treatment rules 
(ITR) (Lavori and Dawson, 2004) using predictive and prescriptive clinical variables that 
manifest quantitative and qualitative treatment interactions, respectively (Carini et al., 2014; 
Gunter et al., 2011). Q-learning (Watkins, 1989; Qian and Murphy, 2011) and A-learning 
(Murphy, 2003; Blatt et al., 2004) are proposed to identify an optimal ITR. Q-learning 
estimates an ITR by directly modelling the Q-function. A-learning only requires posited 
models for contrast functions and uses a doubly robust estimating equation to estimate the 
contrast functions. This makes A-learning more robust to model misspecification than Q-
learning and provides a consistent estimation of an ITR (Schulte et al., 2014). Other 
proposed approaches include semiparametric methods and machine learning methods 
(Zhang et al., 2012; Foster et al., 2011; Zhao et al., 2012; Chakraborty and Moodie, 2013). 
For example, the virtual twins approach (Foster et al., 2011) uses tree-based estimators to 
identify subgroups of patients who show larger than expected treatment effects. Zhang et al. 
(2012, 2013) estimated the optimal ITR by directly maximizing the value function over a 
specified parametric class of treatment rules through augmented inverse probability 
weighting. In contrast, Zhao et al. (2012) proposed outcome weighted learning (O-learning), 
which utilizes weighted support vector machine to maximize the value function. More 
recently, Huang and Fong (2014) proposed a robust machine learning method to select the 
ITR that minimizes a total burden score. Interactive Q-learning (Laber et al., 2014) models 
two ordinary mean-variance functions instead of modeling the predicted future optimal 
outcomes. Fan et al. (2016) proposed a concordance function for prescribing treatment, 
where a patient is more likely to be assigned to a treatment than another patient if s/he has a 
greater benefit than the other patient.
In clinical practice, simple treatment rules such as linear rules, are preferred due to their 
transparency and convenience for interpretation. However, when only linear rules are in 
consideration, many existing methods including semiparametric models and some machine 
learning methods may not yield a rule with optimal performance, because they focus on 
optimization of a surrogate objective function of treatment benefit. Using surrogate objective 
functions may only guarantee the optimality when there is no restriction on the functional 
form of the treatment rules. For example, with O-learning, the objective function is a 
weighted hinge-loss, which yields the optimal rule among nonparametric rules, but may not 
be optimal when the candidate rules are restricted to the linear form. Therefore, learning 
algorithms are desired to derive a treatment rule with guaranteed performance when 
constraints are placed on the class of candidate rules.
An additional consideration is the need to evaluate, through diagnostics, any approach for 
rule estimation. However, less emphasis has been placed on the evaluation of the estimated 
ITR in the context of personalized medicine. Residual plots were used to evaluate model fit 
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for G-estimation (Rich et al., 2010) and Q-learning (Ertefaie et al., 2016). In the recent work 
by Wallace et al. (2016), a dynamic treatment regime (DTR) is estimated by G-estimation 
and double robustness is exploited for model diagnosis. How to evaluate the optimality of an 
ITR in general remains an open research question.
The purpose of this paper is two-fold: we first develop a general approach to identify a linear 
ITR with guaranteed performance; we then propose a diagnostic method to evaluate 
performance of any derived ITR including the proposed one. Our two-stage approach 
separates the estimation of the ITR from its evaluation and the sample used in each stage. 
Specifically, in the first stage, we propose ramp-loss-based (McAllester and Keshet, 2011; 
Huang and Fong, 2014) learning for the estimation and we show that this approach 
guarantees the derived linear ITR to be asymptotically optimal within the class of all linear 
rules. We refer our method as Asymptotically Best Linear O-learning, ABLO. For the 
second stage, in practice, it is infeasible to expect that an ITR that benefits each individual 
can be identified due to the unknown treatment mechanism and the likely omission of some 
prescriptive variables. Thus, we propose a practical solution to calibrate the average ITR 
effect in the population given the observed variables, or in pre-specified important subgroups 
(e.g., patients in most severe state). Specifically, to obtain an ITR evaluation criterion, we 
define the benefit of a candidate ITR as the average difference in the value function between 
those who follow the ITR and those who do not. We then use the ITR benefit as a diagnostic 
measure to evaluate its optimality. Our method exploits the fact that if an ITR is truly 
optimal for all individuals, then for any given patient subgroup, the average outcome for 
patients who are treated according to the ITR should be greater than for those who are not 
treated according to the ITR. On the contrary, if the average outcome of the ITR is worse for 
some patients who follow the ITR than for those who do not, then the ITR is not optimal on 
this subgroup.
Compared to the existing literature, two main contributions of this work are to propose a 
benefit function to calibrate an ITR, and a diagnostic procedure to evaluate optimality of a 
derived ITR, while most of the existing work focuses on the estimation of ITR/DTR. A third 
contribution is to prove asymptotic properties of ITR estimated under the ramp loss (Huang 
and Fong, 2014). Asymptotic results in the existing literature (e.g., Zhao et al., 2012) are 
obtained for the hinge loss. Due to these theoretical results, we can provide valid statistical 
inference procedure for testing optimality of an ITR using asymptotic normality.
In the remainder of this paper, we show that ABLO consistently estimates the ITR benefit 
for a class of candidate rules regardless of two potential pitfalls: 1) the consistency of benefit 
estimator is maintained even though the functional form of the rule is misspecified; 2) the 
rule does not include all prescriptive/tailoring variables and thus the true global optimal rule 
is not in the specified class. We further derive the asymptotic distribution for the proposed 
diagnostic measure. We conduct simulation studies to demonstrate finite sample 
performance and show advantages over existing machine learning methods. Lastly, we apply 
the method to the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial 
on major depressive disorder (MDD), where substantial treatment response heterogeneity 
has been documented (Trivedi et al., 2006; Huynh and McIntyre, 2008). Our analyses 
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estimate an optimal linear ITR, and we demonstrate a large benefit in mildly depressed and 
severely depressed patients but a lack-of-fit among moderately depressed patients.
2. Methodology
Let R denote a continuous variable measuring clinical response after treatment (e.g., 
reduction of depressive symptoms). Without loss of generality, assume a large value of R is 
desirable. Let X denote a vector of subject-specific baseline feature variables, and let A = 1 
or A = −1 denote two alternative treatments being compared. Assume that we observe (Ai, 
Xi, Ri) for the ith subject in a two-arm randomized trial with randomization probability P(Ai 
= a|Xi = x) = π(a|x), for i = 1, …, n.
An ITR, denoted as 𝒟(X), is a binary decision function that maps X into the treatment 
domain A = {−1, 1}. Let P𝒟 denote the distribution of (A, X, R) in which 𝒟 is used to 
assign treatments. The value function of 𝒟 satisfies
V(𝒟) = E𝒟(R) = ∫ R dP𝒟 = ∫ RdP𝒟dP = E RI(A = 𝒟(X))π(A | X) . (1)
In most applications, 𝒟(X) is determined by the sign of a function, f(X), which is referred to 
as the ITR decision function. That is, 𝒟(X) = sign( f (X)). In general settings, f ∈ ℱ can take 
any form, either a parametric function or a non-parametric function. To quantify the benefit 
of an ITR, a measure related to the value function is a natural choice. The mean difference is 
widely used to compare the average effect of two treatments. Analogously, we define the 
benefit function corresponding to an ITR as the difference in the value function between two 
complementary strategies: one that assigns treatments according to 𝒟(X) and the other 
assigns according to the complementary rule −𝒟(X) for any given feature variables X. That 
is, the benefit function for 𝒟(X) = sign( f (X)) is
δ( f (X)) = E R | A = sign( f (X)), X − E R | A = − sign( f (X)), X . (2)
2.1 Estimating Optimal Linear Treatment Rule
To obtain a practically useful and transparent ITR, we consider a class of linear ITR decision 
functions, denoted by ℒ, and estimate the optimal linear function f L
∗ ∈ ℒ, that maximizes 
the value function (1) among this class. To this end, following the original idea of Liu et al. 
(2014), we note that maximizing V(𝒟) is equivalent to minimizing a residual-weighted 
misclassification error given as
E |R − r(X)| I A sign(R − r(X)) ≠ 𝒟(X)π(A | X) ,
where r(X) is any function of X, taken as an approximation to the conditional mean of R 
given X. Thus, we aim to minimize the empirical version of the above quantity, given as
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|Wi|I(AiZi f (Xi) < 0)
π(Ai | Xi)
for f ∈ ℒ, where W i = Ri − r̂(Xi), Zi = sign(Wi), and r̂(X) is obtained from a working model 
by regressing Ri on Xi (Liu et al., 2014).
The above optimization with zero-one loss is a non-deterministic polynomial-time hard (NP-
hard) problem (Natarajan, 1995). To avoid this computational challenge, the zero-one loss 
was replaced by some convex surrogate loss in existing methods, for instance, the squared 
loss or hinge loss. Let f∗ denote the global optimal decision function corresponding to the 
optimal treatment rule among any decision functions. That is, f∗(X) = E(R|A = 1, X) − E(R|
A = −1, X). When ℒ consists of linear decision functions that are far from the global 
optimal rule such that f ∗ ∉ ℒ, estimating optimal linear rule by minimizing the surrogate 
loss (e.g., hinge loss or squared loss) no longer guarantees that the induced value or benefit 
is maximized among the linear class.
In order to obtain the best linear ITR with guaranteed performance, we propose to use an 
authentic approximation loss that will converge to zero-one loss, referred to as the ramp loss 
(McAllester and Keshet, 2011; Huang and Fong, 2014), for value maximization. The ramp 
loss, as plotted in Figure A.1 in the Supplementary Material, has been used in the machine 
learning literature to provide a tight bound on the misclassification rate (McAllester and 
Keshet, 2011; Collobert et al., 2006). Mathematically, this function can be expressed as






2 < u <
s
2) (3)
where s is a tuning parameter to be chosen in a data-adaptive fashion. Clearly, when s 
converges to zero, the ramp loss function converges to the zero-one loss; thus, we expect that 
the estimated rule from this loss function should approximately maximize the value function 
among class ℒ.
Specifically, with the ramp loss (3), we propose to estimate the optimal linear ITR decision 
function, f L
∗(X), by minimizing the penalized weighted sum of ramp loss of a linear decision 
function f(X) = β0 + XT β,
L( f ) = C ∑
i = 1




where C is the cost parameter. Because the ramp loss is not convex, we solve the 
optimization by the difference of convex functions algorithm (DCA) (An et al., 1996). First, 
we express hs(u) as the difference of two convex functions, 
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s )+, where function (x)+ denotes the positive 
part of x. Let ηi denote ZiAif(Xi). With the DCA, starting from an initial value for η, the 
minimization in (4) can be carried out iteratively, and denote the solution as









where ĥ2, s(ηi, ηi
0) = h2, s(ηi
0) + h2, s′ (ηi
0)ηi, and h2, s′ (u) = − I(u/s < − 1/2)/s. The iteration stops 
when the change in the objective function is less than a pre-specified threshold. Detailed 
steps in estimating β are provided in Section A1 of the Supplementary Materials.
We denote the optimal linear decision function obtained by the above procedure as 
f L
∗̂(X) = β̂0 + X
T β̂ and denote the optimal ITR as sign( f L
∗̂(X)). In the Supplementary Materials 
(Section A2), we show that f L
∗̂ converges to the true best linear rule, f L
∗, asymptotically, at a 
slower rate than the usual root-n rate. We refer the proposed estimation procedure as 
Asymptotically Best Linear O-learning, ABLO. We also prove the asymptotic normality of β̂
and the estimated benefit function, which provides justification of the inference procedures 
proposed in the next two sections.
2.2 Performance Diagnostics for the Estimated ITR
ABLO guarantees that the optimal value among the class ℒ is achieved asymptotically. 
Nevertheless, the optimal linear rule f L
∗(X) may still be far from the global optimal, f∗, such 
that for some important subgroups, f L
∗(X) may be non-optimal or even worse than the 
complementary treatment rule. Therefore, an empirical measure must be constructed to 
evaluate the performance of an estimated ITR.
To develop a practically feasible diagnostic method for any estimated ITR, given by 
sign( f̂ (X)) we note that if f̂ (X) is truly optimal among any decision functions in ℱ, i.e., f̂ (X)
has the same sign as f∗(X), then for any subgroup defined by X ∈ 𝒞 for a given set 𝒞 in the 
domain of X, the value function for those subjects whose treatments are the same as 
sign( f̂ (X)). should always be larger than or equal to the value function for those subjects with 
the same X ∈ 𝒞, but whose treatments are opposite to sign( f̂ (X)). This is because
E
RI A = sign( f̂ (X))
π(A | X) |X
− E
RI A = − sign( f̂ (X))
π(A | X) |X = I( f
∗(X) > 0)E(R | A = 1, X) + I( f ∗(X) ≤ 0)E(R | A = − 1, X) − I( f ∗(X) > 0)E
(R | A = − 1, X) − I( f ∗(X) ≤ 0)E(R | A = 1, X) = | f ∗(X)| ⩾ 0.
It then follows that the group-average benefit for f̂ , defined as
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δ𝒞( f̂ ) ≡ E
RI A = sign( f̂ (X))
π(A | X) |X ∈ 𝒞 − E
RI A = − sign( f̂ (X))
π(A | X) |X ∈ 𝒞 ,
should be non-negative. On the other hand, if δ𝒞( f̂ ) ⩾ 0 holds for any subset 𝒞, then the 
above derivation also indicates that f̂ (X) must have the same sign as f∗(X), i.e., f̂ (X) is the 
optimal treatment rule for subjects in 𝒞.
These observations suggest a diagnostic measure δ𝒞( f̂ ) for any subgroup 𝒞. Specifically, we 
propose an empirical ITR diagnostic measure as
δ̂𝒞( f̂ ) =
∑i = 1n I Xi ∈ 𝒞, Ai = sign( f̂ (Xi)) − I Xi ∈ 𝒞, Ai = − sign( f̂ (Xi)) Ri/π(Ai | Xi)
∑i = 1n I(Xi ∈ 𝒞)
.
Because δ̂𝒞( f̂ ) approximates δ𝒞( f̂ ) the measure δ̂𝒞( f̂ ) is expected to be positive with a high 
probability if f̂ (X) is close to the global true optimal. Furthermore, the evidence that δ̂𝒞( f̂ ) is 
positive for a rich class of subsets 𝒞 will support the approximate optimality of f̂  in the 
class. However, because it is infeasible to exhaust all subgroups, we suggest a class of pre-
specified subgroups 𝒞1, …, 𝒞m and calculate the corresponding δ̂𝒞1
( f̂ ), …, δ̂𝒞m
( f̂ ). An 
aggregated diagnostic measure is Δ̂( f̂ ) = min δ̂𝒞1
( f̂ ), …, δ̂𝒞m
( f̂ ) . A positive value of Δ̂( f̂ )
implies approximate optimality of f̂  when m is large enough. In practice, we consider 𝒞k to 
be pre-specified groups or the sets determined by the tertiles of each component of X, for 
example, the jth component of X below its first tertile, between the first and the second 
tertiles, or above the second tertile. Moreover, using the proposed diagnostic measure, by 
examining the subsets 𝒞 (or tertiles defined by variables) with negative or close to zero 
values of δ̂𝒞( f̂ ), we can identify subgroups or components of X for which the estimated rule 
f̂  may not be sufficiently optimal. Thus, we can further improve the rule estimation in this 
subgroup to obtain an improved ITR.
If the same data are used for estimating the optimal ITR and performing diagnostics, the 
latter may not be an honest measure of performance (Athey and Imbens, 2016). Thus, we 
suggest the following sample-splitting scheme. Divide the data into K folds, and denote 
f̂ ( − k) as the optimal ITR obtained using data without the kth-fold. Next, each f̂ ( − k) is 
calibrated on the kth-fold data using the diagnostic measure and then averaged. Let nk 
denote the sample size of the kth-fold, and let Ik index subjects in this fold. The honest 
diagnostic measure for subgroup 𝒞 is estimated by δ̂𝒞( f̂ ) =
1
K ∑k = 1K δ̂𝒞(k), where
Qiu et al. Page 7
















i: i ∈ Ik
I Ai = sign( f̂
( − k)(Xi)) − I Ai = − sign( f̂
( − k)(Xi)) Ri/π(AiXi) .
We will implement this scheme in subsequent analysis.
2.3 Inference Using the Diagnostic Measure
The proposed diagnostic measure, δ̂𝒞( f̂ ), can be used to compare different ITRs and non-
personalized rules, make comparisons within certain subgroups, and assess heterogeneity of 
ITR benefit (HTB) across subgroups. Hypotheses of interest may include:
• Test significance of the optimal linear rule compared to the non-personalized rule 
in the overall sample, i.e., H0:δ( f L
∗) − δ0 = 0, v.s. H1:δ( f L
∗) − δ0 > 0, where δ0 is 
the average treatment effect of a non-personalized rule (difference in the mean 
response between treatment groups). For this purpose, we can construct the test 
statistic based on δ̂𝒞( f̂ ) − δ0, where f̂  is obtained from any method, and 𝒞 is the 
whole population. We reject the null hypothesis at a significance level of α if the 
(1−α)-confidence interval with ∞ as the upper bound for δ̂𝒞( f̂ ) − δ0 does not 
contain 0.
• Test significance of the optimal linear rule compared to the non-personalized rule 
in a subgroup k, i.e., H0:δ𝒞k
( f L
∗) − δ0k = 0 v.s., H1:δ𝒞k
( f L
∗) − δ0k > 0 where δ0k is 
the average treatment effect in the subgroup. The same test statistic as the 
previous one can be used but with 𝒞 = 𝒞k.










( f̂ ) − δ̂𝒞K
( f̂ ), ⋯, δ̂𝒞K − 1
( f̂ ) − δ̂𝒞K
( f̂ )). 
It can be shown that T asymptotically follows χK − 1
2  under H0, so we reject H0 
when T is larger than the (1 − α)-quantile of χK − 1
2 .
• Test the non-optimality of the best linear rule f L
∗ in a subgroup 𝒞 by evaluating 
H0:δ𝒞( f L
∗) ⩾ 0 v.s. H1:δ𝒞( f L
∗) < 0. For this purpose, we can directly use δ̂𝒞( f̂ )
and reject the null hypothesis if the confidence interval with lower bound of −∞ 
does not contain zero.
The asymptotic properties of β̂ and δ̂𝒞( f̂ ) are required to perform inference above. Based on 
the theoretical properties (asymptotic normality) given in the Supplementary Materials 
(Section A2), we propose a bootstrap method to compute confidence interval for the 
diagnostic measure. We denote the bth bootstrap sample as (A∼i
(b), X∼i
(b), R∼i
(b)), where i = 1, 2, 
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⋯, n, and re-estimate residuals as W∼i
(b) in (5). Next, we re-fit treatment rule f








(b)( f∼(b)), b = 1, 2, ⋯, B.
3. Simulation Studies
3.1 Simulation Design
For all simulation scenarios, we first generated four latent subgroups of subjects based on 10 
feature variables X = (X1, ⋯, X10) informative of optimal treatment choice from a pattern 
mixture model. Treatment A = 1 has a greater average effect for subjects in subgroups 1 and 
2, and the alternative treatment −1 has a greater average effect in subgroups 3 and 4. Within 
each subgroup, X were independently simulated from a normal distribution with different 
means and standard deviation of one. Two settings were considered. In Setting 1, the means 
of the feature variables for subjects in the four subgroups were (1, 0.5, −1, −0.5), 
respectively. In Setting 2, the means were (1, 0.3, −1, −0.3). Five noise variables U = (U1, ⋯, 
U5) not contributing to R were independently generated from the standard normal 
distribution and included in the analyses in order to assess the robustness of each method in 
the presence of noise features. The treatments for each subject were randomly assigned to 1 
or −1 with equal probability, and the number of subjects in each subgroup was equal.
Three additional feature variables W, V, and S were generated to be directly associated with 
the clinical outcome R. Here, W is an observed prescriptive variable informative of the 
optimal treatment, V is a prognostic variable predictive of the outcome but not the optimal 
treatment, and S is an unobserved prescriptive variable not available in the analysis. The 
clinical outcome for subjects in the kth subgroup was generated by
R = 1 + I(A = 1)(δ1k + α1k ∗ W + β1k ∗ S) + I(A = − 1)(δ2k + α2k ∗ W + β2k ∗ S) + V + e,
where e ∼ N(0, 0.25), V, W, and S are i.i.d. and follow the standard normal distribution, 
δ = [δlk]2 ∗ 4 =
1 0.3 0 0
0 0 1 0.3 , α = [αlk]2 ∗ 4 =
1 0.6 0.5 0.3
0.5 0.3 1 0.6 , and β =2α within each group k, 
there is a qualitative interaction between treatment and W. Additional visualization of the 
simulation setting is provided in the Supplementary Materials (Figure A.2).
The benefit function of the theoretical global optimal ITR decision function, denoted as f∗, 
was computed numerically by simulating the clinical outcome R under treatment 1 or −1, 
using all observed feature variables (i.e., X, W, and V), and taking the average difference of 
R under the true optimal and non-optimal treatments using a large independent test set of N 
= 100, 000. In practice, this global optimum may not be attained by a linear rule due to the 
unknown and potentially nonlinear true optimal treatment rule. The theoretical optimal 
linear rule f L
∗ was computed numerically using the observed variables and maximizing the 
value function in the class of all linear rules under each simulation model (details in the 
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Supplementary Materials; Section A3). The benefit of f L
∗ was then computed with a large 
independent test set of N = 50, 000.
For each simulated data set, predictive modeling (PM), Q-learning, O-learning, and ABLO 
were applied to estimate the optimal ITR. For PM, we considered a random forest-based 
prediction related to the virtual twins approach of Foster et al. (2011). PM first applies 
random forest on R, including all observed feature variables Z = (X, U, W, V) and treatment 
assignments. It next predicts the outcome for the ith subject given (Zi, Ai = 1) and (Zi, Ai = 
−1), denoted as R̂1i and R̂−1i, respectively. The optimal treatment for the subject is 
sign(R̂1i − R̂−1i). Q-learning was implemented by a linear regression including all the 
observed feature variables, treatment assignments, and their interactions. Benefit of the 
estimated optimal ITR under each method and was computed by δ̂𝒞( f̂ ) in Section 2.2.
In the simulations, observed feature variables Z were used in all methods, while the 
unobserved prescriptive variable S and latent subgroup membership were not included. 
Linear kernel was used for O-learning and ABLO. Five-fold cross validation was used to 
select the tuning parameters C and s. For each method, the optimal treatment selection 
accuracy and ITR benefit were estimated using two-fold cross validation with equal size of 
training and testing sets. The training set was used to estimate the ITR and the testing set 
was used to estimate the ITR benefit and accuracy. Bootstrap was used to estimate the 
confidence interval of the ITR benefit under the estimated rule. Coverage probabilities were 
reported to evaluate the performance of the inference procedure. To evaluate performance on 
subgroups, we partitioned W, V, X1, and U1 into three groups based on values in the 
intervals (−∞, −0.5), [−0.5, 0.5], or (0.5, ∞). We calculated the HTB test for the candidate 
variables and tested the difference between the estimated rules and the overall non-
personalized rules.
3.2 Simulation Results
Results from 500 replicates are summarized in Table 1, 2, 3, Figure 1 and 2. For both 
simulation settings, ABLO with linear kernel has the largest optimal treatment selection 
accuracy regardless of the sample size, and it is also close to the maximal accuracy rate 
based on the theoretical best linear rule. In addition, ABLO estimates the ITR benefit closest 
to the true global maximal value of 0.678 on the overall sample, and it is almost identical to 
the benefit estimated by the theoretical best linear rule when the sample size is large (= 800 
training, 800 testing). PM, Q-learning, and O-learning all underestimate the ITR benefit, 
especially when the sample size is smaller (N = 400 training, 400 testing), and thus they do 
not attain the maximal value of the theoretical optimal linear rule. Based on the empirical 
standard deviation, we also observe that ABLO is more robust than all other methods. For all 
methods, as the sample size increases, the treatment selection accuracy increases and the 
estimated mean benefit is closer to the true optimal value. Furthermore, the estimated ITR 
benefit increases as the accuracy rate increases. The coverage probability of the overall 
benefit of the best linear rule is close to the nominal level of 95% using ABLO, but less than 
95% using other methods. The coverages are not nominal for O-learning, Q-learning, and 
PM, since their benefit estimates are biased when the candidate rules are misspecified (e.g., 
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true optimal rule is not linear). This is because they use a surrogate loss function that does 
not guarantee convergence to the indicator function in the benefit function δ𝒞( f̂ ).
The performance of estimation of the subgroup ITR benefit shows similar results, whereby 
ABLO outperforms O-learning, Q-learning, and PM in both settings, especially when W ∈ 





∗) = 0, k= 1 or 2, using the HTB test with a null distribution of χ2
2. The 
rejection rates of the HTB tests of V and U1 that do not have a difference in ITR benefit 
across subgroups correspond to the type I error rate. The type I error rates of ABLO are 
close to 5%, but conservative for the other three methods. To examine the power, we test the 
effect of W on the benefit across subgroups defined by discretizing W at −0.5 and 0.5. The 
power of ABLO is much greater than the other three methods especially when the sample 
size is small. The other three methods underestimate the benefit function, and thus the HTB 
test is conservative and less powerful.
Lastly, we test the difference in the benefit between the ITRs and the non-personalized rule 
in the overall sample and the subgroups. Table 3 shows that with a sample size of 800, 
ABLO is the only method that provides a significantly better benefit than the non-
personalized rule with a large power (> 80%). When the sample size is large (N = 1600), 
ABLO, Q-learning, and O-learning have a power of ⩾ 88%. As for the subgroups, the ITR 
estimated by ABLO is more likely to outperform the non-personalized rule on the subgroups 
showing a larger true benefit (i.e., when W > 0.5).
Additional simulation results varying the strength of the prescriptive feature variable W are 
described in the Supplementary Materials (Section A4).
4. Application to the STAR*D Study
STAR*D (Rush et al., 2004) was conducted as a multi-site, multi-level, randomized 
controlled trial designed to compare different treatment regimes for major depressive 
disorder when patients fail to respond to the initial treatment of Citalopram (CIT) within 8 
weeks. The primary outcome, Quick Inventory of Depressive Symptomatology (QIDS) score 
(ranging from 0 to 27), was measured to assess the severity of depression. A lower QIDS 
score indicates less symptoms and thus reflects a better outcome. Participants with a total 
QIDS score under 5 were considered to experience a clinically meaningful response to the 
assigned treatment and were therefore remitted from future treatments.
The trial had four levels of treatments (e.g., see Figure 2.3 in Chakraborty and Moodie 
(2013)); we focused on the first two levels. At the first level, all participants were treated 
with CIT for a minimum of 8 weeks. Participants who had clinically meaningful response 
were excluded from level-2 treatment. At level-2, participants without remission with level-1 
treatment were randomized to level-2 treatment based on their preference to switch or 
augment their level-1 treatment. Patients who preferred to switch treatment were randomized 
with equal probability to bupropion (BUP), cognitive therapy (CT), sertraline (SER), or 
venlafaxine (VEN). Those who preferred augmentation were randomly assigned to CIT
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+BUP, CIT+buspirone (BUS), or CIT+CT. If a patient had no preference, s/he was 
randomized to any of the above treatments.
The clinical outcome (reward) is the QIDS score at the end of level-2 treatment. There were 
788 participants with complete feature variable information included in our analysis. We 
compared two categories of treatments: 1) treatment with selective serotonin reputake 
inhibitors (SSRIs, alone or in combination): CIT+BUS, CIT+BUP, CIT+CT, and SER; and 
2) treatment with one or more non-SSRIs: CT, BUP, and VEN. Feature variables used to 
estimate the optimal ITR included the QIDS scores measured at the start of level-2 treatment 
(level 2 baseline), the change in the QIDS score over the level-1 treatment phase, patient 
preference regarding level-2 treatment, and demographic variables (gender, age, race), and 
family history of depression. As the randomization to treatment was based on patient 
preference, we estimated π(Ai|Xi) using empirical proportions based on preferring switching 
or no preference, because patients who preferred augmentation were all treated with an SSRI 
and were excluded from the analysis.
We applied four methods to estimate the optimal ITR for patients with MDD who did not 
achieve remission with 8 weeks of treatment with CIT. For all methods, we randomly split 
the sample into a training and testing set with a 1:1 ratio and repeated the procedure 500 
times. The value function and ITR benefits were evaluated on the testing set. PM, Q-
learning, O-learning, and ABLO are compared in Figure 3. The non-personalized rules yield 
a QIDS score of 10.16 for SSRI and 9.60 for non-SSRI, with a difference of 0.56. The ITR 
estimated by ABLO yields a QIDS score of 9.32 (sd = 0.23), which is smaller than PM 
(9.69, sd = 0.38), Q-learning (9.50, sd=0.35), and O-leaning (9.55, sd = 0.41). The overall 
ITR benefit estimated by ABLO (1.11, sd = 0.46) is much larger than PM (0.38, sd = 0.76), 
Q-learning (0.77, sd = 0.70), and O-leaning (0.66, sd = 0.82). The ITR benefit based on 
ABLO is also larger than the non-personalized rule (1.11 versus 0.56). The final ITR 
estimated by ABLO is reported in Supplementary Materials (Section A5).
Clinical literature suggests that the baseline MDD severity may be a moderator for treatment 
response (Bower et al., 2013). In addition, baseline MDD severity is highly associated with 
suicidality; thus, patients with severe baseline MDD (QIDS ⩾ 16) represent an important 
subgroup. We partitioned patients into mild (QIDS ≤ 10), moderate (QIDS ∈ [11, 15]), and 
severe (QIDS ⩾ 16) MDD subgroups. Using ABLO and the HTB test, baseline QIDS score 
was found to be significantly associated with ITR benefit: two subgroups show a large 
positive ITR benefit (2.22 for the mild group and 2.02 for the severe group), whereas the 
moderate subgroup shows no benefit (ITR benefit = −0.18). This result indicates that 
patients with mild or severe baseline depressive symptoms (high or low QIDS score) might 
benefit from following the estimated linear ITR. For patients who are moderately depressed 
(QIDS ∈ [11, 15]), the linear ITR estimated from the overall sample does not adequately fit 
the data and does not outperform a non-personalized rule. Thus, we re-fit a linear rule using 
ABLO for the moderate subgroup only. The re-estimated ITR yields a lower average QIDS 
score of 8.93 (sd = 0.35), with a much improved subgroup ITR benefit of 0.60 (sd = 0.70). 
This analysis demonstrates the advantage of the ITR benefit diagnostic measure, the HTB 
test, and the value of re-fitting the ITR on subgroups showing a lack-of-fit.
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In this work, we propose a diagnostic measure (benefit function) to compare candidate ITRs, 
a machine learning method (ABLO) to estimate the optimal linear ITR, and several tests for 
goodness-of-fit. In practice, often not all predictive and prescriptive variables that influence 
heterogeneous responses to treatment are known and collected. Thus, it is unrealistic to 
expect that an ITR that benefits each and every individual can be identified. Our practical 
solution proposes to evaluate the average ITR effect over the entire population and on 
vulnerable or important subgroups. Although we focus on linear decision functions here, it is 
straightforward to extend ABLO to other simple decision functions such as polynomial rules 
by choosing other kernel functions (i.e., polynomial kernel). ABLO can also be applied to 
observational studies using propensity scores to replace π(A|X) under the assumption that 
the propensity score model is correctly specified. We prove the asymptotic properties of 
ABLO and identify a condition to avoid the non-regularity issue (in Supplementary Material 
Section A2). In practice, when such issue is of concern, adaptive inference (Laber and 
Murphy, 2011) can be used to construct confidence intervals.
ABLO can consistently estimate the ITR benefit function regardless of misspecification of 
the rule by drawing a connection with the robust machine learning approach for 
approximating the zero-one loss. We provide an objective diagnostic measure for assessing 
optimization. In our method, prescriptive variables mostly contribute to the estimation of the 
optimal treatment rule while predictive variables mostly contribute to the development of the 
diagnostic measure and assessment of the benefit of the optimal rule. Future work will 
consider methods to distinguish these two sets of variables, which potentially overlap.
ABLO is slower than O-learning because it involves iterations of quadratic programming 
when applying the DCA. In addition, certain simulations show that the algorithm can be 
slightly sensitive to the initial values in extreme cases (examples provided in Figure A.5 in 
the Supplementary Materials). However, our numeric results show that O-learning estimators 
serve as adequate initial values leading to fast convergence of the DCA. Another limitation 
is that the current methods only apply to single-stage trials. ABLO can be extended to 
multiple stage setting following a similar backward multi-stage O-learning in Zhao et al. 
(2015). The objective function in multi-stage O-learning will be replaced by the ramp loss 
and the benefit function will be extended with some attention to subjects whose observed 
treatment sequences are partially consistent with the predicted optimal treatment sequences.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Simulation results: Overall ITR benefit and optimal treatment accuracy rates for the four 
methods. Dotted-dashed lines represent the benefit (top panels) and accuracy (bottom 
panels) under the theoretical global optimal treatment rule f∗. Dashed lines represent the 
benefit and accuracy under the theoretical optimal linear rule f L
∗. The methods being 
compared are (from left to right): PM: predictive modeling by random forest; Q-learning: Q-
learning with linear regression; O-learning: improved single stage O-learning (Liu et al., 
2014); ABLO: asymptotically best linear O-learning. This figure appears in color in the 
electronic version of this article.
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Simulation results: Subgroup ITR benefit for the four methods. Dotted-dashed lines 
represent the benefit under the theoretical global optimal treatment f∗. Dashed lines 
represent the benefit under the theoretical optimal linear rule f L
∗. The methods being 
compared are (from left to right): PM: predictive modeling by random forest; Q-learning: Q-
learning with linear regression; O-learning: improved single stage O-learning (Liu et al., 
2014); ABLO: asymptotically best linear O-learning. This figure appears in color in the 
electronic version of this article.
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STAR*D analysis results: Distribution of the estimated ITR benefit (the higher the better) 
and QIDS score (the lower the better) at the end of level-2 treatment for the four methods 
(based on 500 cross-validation runs). The methods being compared are (from left to right): 
PM: predictive modeling by random forest; Q-learning: Q-learning with linear regression; 
O-learning: improved single stage O-learning (Liu et al., 2014); ABLO: asymptotically best 
linear O-learning. This figure appears in color in the electronic version of this article.
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Table 2
Simulation results: probability of rejecting the null hypothesis that the treatment benefit across subgroups is 
equivalent by the HTB test.
Setting 1. Four region means = (1, 0.5, −1, −0.5).
W X1 V U1
N = 800
PM 0.16 0.05 0.03 0.02
Q-learning 0.18 0.06 0.03 0.03
O-learning 0.21 0.05 0.03 0.03
ABLO 0.42 0.07 0.05 0.06
N = 1600
PM 0.52 0.05 0.05 0.02
Q-learning 0.61 0.05 0.04 0.02
O-learning 0.71 0.04 0.04 0.02
ABLO 0.84 0.05 0.05 0.03
Setting 2. Four region means = (1, 0.3, −1, −0.3).
N = 800
PM 0.12 0.03 0.02 0.02
Q-learning 0.17 0.04 0.03 0.04
O-learning 0.15 0.03 0.03 0.03
ABLO 0.34 0.06 0.04 0.05
N = 1600
PM 0.42 0.06 0.04 0.03
Q-learning 0.56 0.07 0.04 0.03
O-learning 0.57 0.07 0.03 0.03
ABLO 0.74 0.10 0.04 0.05
*
W has strong signal; X1 has weak signal; V and U1 have no signal.
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Table 3
Simulation results: Comparison of the ITR to the non-personalized universal rule. The proportion of rejecting 
the null that the ITR has the same benefit as the universal rule∗ are reported for the overall sample and by 
subgroups.
Setting 1. Four region means = (1, 0.5, −1, −0.5).
Overall W < −0.5 W ∈ [−0.5, 0.5] W > 0.5
N = 800
PM 0.22 0 0.09 0.33
Q-learning 0.37 0.02 0.20 0.40
O-learning 0.39 0.02 0.20 0.43
ABLO 0.86 0.07 0.47 0.78
N = 1600
PM 0.76 0.02 0.38 0.83
Q-learning 0.92 0.05 0.59 0.90
O-learning 0.95 0.06 0.67 0.94
ABLO 0.99 0.08 0.79 0.98
Setting 2. Four region means = (1, 0.3, −1, −0.3).
N = 800
PM 0.18 0.01 0.07 0.27
Q-learning 0.35 0.03 0.17 0.37
O-learning 0.31 0.03 0.17 0.35
ABLO 0.82 0.07 0.43 0.74
N = 1600
PM 0.72 0.03 0.38 0.75
Q-learning 0.88 0.05 0.57 0.86
O-learning 0.90 0.07 0.59 0.86
ABLO 0.99 0.12 0.77 0.97
*
For Setting 1, the mean difference (sd) of the universal rule is 0.09(0.08) for N = 800 and 0.07(0.05) for N = 1600.
For Setting 2, the mean difference (sd) of the universal rule is 0.11(0.08) for N = 800 and 0.08(0.05) for N = 1600.
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